NCT01871415已完成3 期
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR PLUS METFORMIN COMBINATION THERAPY COMPARED WITH PLACEBO PLUS METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 7
- 主要终点
- Change in HbA1c
研究概览
简要总结
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of aleglitazar in combination with metformin in patients with Type 2 diabetes mellitus who are inadequately controlled with metformin monotherapy. Patients will be randomized to receive either aleglitazar 150 mcg orally daily or placebo for 26 weeks in combination with their pre-existing metformin regimen and dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient, >/= 18 years of age
- •Type 2 diabetes mellitus treated with stable metformin monotherapy for at least 12 weeks prior to screening; metformin dose should be >/= 1500 mg/day (or individual maximum tolerated dose), but no more than the maximum dose specified in the label
- •HbA1c >/= 7% and </= 9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit
- •Fasting plasma glucose </= 13.3 mmol/L (</= 240 mg/dL) at pre-randomization visit
- •Agreement to maintain diet and exercise habits implemented during the run-in phase during the full course of the study
排除标准
- •Pregnant women, women intending to become pregnant during the study period, currently lactating women, or women of child-bearing potential not using highly effective, medically approved birth control methods
- •Diagnosis or history of:
- •Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes
- •Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months
- •Any previous treatment with thiazolidinedione or with a dual PPAR agonist
- •Any body weight lowering or lipoprotein-modifying therapy (e.g. fibrates) within 12 weeks prior to screening with the exception of stable (>= 1 month) statin therapy
- •Prior intolerance to fibrate
- •Treatment with anti-diabetic medication other than metformin in the last 12 weeks prior to screening
- •Triglycerides (fasting) > 4.5 mmol/L (> 400 mg/dL) at screening or within 4 weeks prior to screening
- •Clinically apparent liver disease
- •Anemia at or within 4 weeks prior to screening
- •Inadequate renal function
- •Symptomatic congestive heart failure NYHA Class II-IV at screening
- •Myocardial infarction, acute coronary syndrome or transient ischemic attack/stroke within 6 months prior to screening visit
- •Known macular edema at screening or prior to screening visit
- •Diagnosed and/or treated malignancy (except for basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past 5 years
- •Uncontrolled hypertension
- •History of active substance abuse (including alcohol) within the past 2 years
研究组 & 干预措施
Aleglitazar + metformin
Experimental
干预措施: aleglitazar (Drug)
Aleglitazar + metformin
Experimental
干预措施: metformin (Drug)
Placebo + metformin
Active Comparator
干预措施: metformin (Drug)
Placebo + metformin
Active Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Change in HbA1c
时间窗: from baseline to Week 26
次要结局
- Change in lipids(from baseline to Week 26)
- Change in fasting plasma glucose (FPG)(from baseline to Week 26)
- Responder rates, defined as target HbA1c: < 7.0%, < 6.5% at Week 26(26 weeks)
- Change in homeostatic index of insulin sensitivity (by HOMA-IS)(from baseline to Week 26)
- Change in homeostatic index of beta cell function (by HOMA-BFC)(from baseline to Week 26)
- Change in markers of insulin sensitivity/cardiovascular risk(from baseline to Week 26)
- Safety: Incidence of adverse events(approximately 30 weeks)
研究者
相似试验
已完成
3 期
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin TherapyDiabetes Mellitus Type 2NCT01691989Hoffmann-La Roche197
已完成
3 期
A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic TherapyDiabetes Mellitus Type 2NCT01871428Hoffmann-La Roche13
已完成
3 期
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin AloneDiabetes Mellitus Type 2NCT01691846Hoffmann-La Roche200
已完成
3 期
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic TherapyDiabetes Mellitus Type 2NCT01691755Hoffmann-La Roche196
终止
2 期
Study of RO6807952 in Patients With Diabetes Mellitus Type 2Diabetes Mellitus Type 2NCT01516476Hoffmann-La Roche2